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Abstract: Three commercially available preparations of human  nnmunoglobuhn for intravenous use (IVIgG), namely Gatmmune  N, 
Sandoglobuhn and Intraglobm F, were tested for their ability to modulate human  neutrophfl function in ~ltro IVIgG consistently 
stimulated the neutrophfl respiratory burst  at concentrations of 0 5 to I mg/ml, concentrations readily achieved m ,n~ o by moderate-dose 
therapy Superoxlde (O z ) release was increased by 3 5~4 5 nmol per 5 x 105 cells at these concentrations of  IVlgG, and H202 
production increased m a dose-dependent fashion up to 8 mg/ml IVIgG Lumlnol-dependent chemiluminescence (CL) was also directly 
stimulated by IVIgG In addition, the effects of  both soluble and pamcula te  btlmulators (N-formyl-methlonyMeucyl-phenylalanme, 
phorbol myrlstate acetate and opsomzed zymosan) on the neutrophll respiratory burst were enhanced by IVIgG In a filter assay of 
neutrophll mlgrahon,  using a modified Boyden chamber,  no consistent effect on neutrophll Iocomohon or chemotax~s could be demon- 
strated The effect of  IVIgG on neutrophfl metabohsm may contribute to its beneficial therapeuhc effect m severe, hfe-threatenlng 
infections 
Key words: Neutrophfl.  Intravenous immunoglobuhn.  Superoxlde. Hydrogen peroxide. Chemdummescence.  Chemotaxls 
Introduction 
The use of  intravenous immunoglobuhn (IVIgG) is 
established in the treatment of  idiopathic thrombo- 
cytopenic purpura  (ITP), it may be utlhzed as first- 
line therapy in children and as second-hne therapy 
Co,  e~pondence Dr John W M Lawton. Reader in Immunol-  
ogy. Depar tment  of  Pathology. Unl.~erslty of  Hong Kong. Hong 
Kong 
.4hhtevlatlons IVIgG. normal  human  lmmunoglobuhn  for in- 
travenous use. CL. chemiluminescence. ITP. ldlopathlc throm- 
bocytopemc purpura.  AIDS. acquired lmmunodeficlency syn- 
drome. HBSS. Hank ' s  balanced salt solution. OZ. opsonlzed 
zymosan.  PMA.  phorbol myrlstate acetate. FMLP.  N-formyl-L- 
methlonyl-L-leucyl-L-phenylalanlne. SOD. superoxlde dlsmuta- 
se. D C F H - D A .  2'.7'-dlchlorofluorescln dlacetate. DCFH.  2'.7'- 
dlchlorofluorescln. DCF.  2".7'-dlchlorofluorescean. PBS. phos- 
phate-buffered sahne, cpm. counts  per minute. BSA. bovine ~e- 
rum albumin. HSA. human  serum albumin. IV. intravenous. 
IM. intramuscular  
m adults who are refractory to steroids (Imbach et 
a l ,  1981: Newland, 1987). It is also effectwe m the 
treatment of  alloimmune neonatal neutropenla (Ba- 
rundun et al., 1982) and post-transfusion purpura 
(Mueller-Eckhardt et al., 1983). Regular infusion of 
IVIgG m primary hypogammaglobuhnemla and re- 
lated disorders may, in fact, be superior to conven- 
tional replacement regimens using intramuscular 
IgG (McClelland and Yap, 1987). It is of value m 
the treatment of  infants with AIDS (Calvelh and 
Rubmsteln, 1986), however, ~ts place in the treat- 
ment of severe refections m the lmmuno-compro-  
raised host has not yet been clearly defined (Yap, 
1987) 
The mechanism by which IVIgG decreases cell 
destructmn m the immune cytopenias has been a 
subject of speculation (Imbach, 1983, Salama et al., 
1983) Jungl et al. (1986) demonstrated that IVIgG 
preparations could interact wnh Fc receptors of  hu- 
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man monocytes and macrophages to lnh~blt the 
phagocytosis of  IgG-sensitized erythrocytes High- 
dose IVIgG may also modulate the immune re- 
sponse by reducing the lymphocyte CD4 CD8 ratio 
and by reducing B-cell lmmunoglobuhn synthesis 
(Tsubaklo et al., 1983, Dammacco  et a l ,  1986) 
Since the neutrophll is central to the acute inflam- 
matory  response and in defence against most bacte- 
rial pathogens, it is important  to know whether 
neutrophil functions are m any way modulated by 
IVIgG in the concentrations achieved by high-dose 
therapy In the present study we set out to examine 
the effect of three commercially available IVlgG 
preparations on neutrophll function m vitro, r e ,  
superoxlde Ion (O2-)  release, H202 production, 
chemiluminescence (CL) and chemotaxis 
Materials and Methods 
Intravenous mummoglohulm 
Three IVIgG preparations were used in this study 
Intraglobln F (Blotest Pharma Gmbh,  Drelelch, 
F R G ,  lot 412087), Sandoglobuhn (Sandoz Phar- 
maceuticals Corp., East Haven, N J, lot 7 369.157 0) 
and Gamlmune  N (Cutter Biological, Berkeley, 
CA, lot 40C13A). Sandoglobuhn is prepared by the 
method developed by the Swiss Red Cross, Cohn 
effluent III  IgG from pooled human plasma is treat- 
ed at low pH (4- 4.5) in the presence of a very, low 
concentraUon of porcine pepsin Gamlmune  ~s 
made by essentially the same method except that 
pepsin is omitted. In contrast, Intraglobln F ~s 
chemically modified, Cohn effluent III IgG is treat- 
ed with fi-proplolactone These preparations all 
contain > 9 8 %  IgG, Gamlmune  N contains negh- 
glble amounts of  aggregates, dimers and fragments 
Sandoglobuhn contains < 1% aggregates, 9 10% 
dlmers and no detectable fragments Intraglobin F 
contains no detectable aggregates, 3 4% dimers 
and 9 10% fragments (Lundblad et a l ,  1987) 
Intraglobln F and Gamlmune  N are supphed as 
solutions of 50 mg protein/ml. For convenience 
these were diluted to 40 mg/ml with Hank 's  bal- 
anced salt solution (HBSS), pH 7.4, so that when 
further diluted 1/'10 under experimental conditions 
a final concentration of 4 mg/ml was obtained 
Sandoglobuhn was supphed freeze-dried, and was 
reconstituted m HBSS at a concentrauon of 40 rag,' 
ml Doubling dilutions were made in HBSS for 
dose-response experiments Concentrations of  
IVIgG used in ~ltro ranged from 0 25 mg:ml to 8 
mg/ml. High-dose IVIgG therapy' ~s known to 
achieve serum concentrations of the order of  8 rag/ 
ml (Pirofsky, 1987) 
Each IVIgG contains career  sugar as a stabfllzcr 
and it has been shown previously that both maltose 
and glucose inhibit the stimulatory effect of  IVIgG 
on neutrophlls, measured by O2 release (Koch et 
al, 1984) Therefore, in all experiments the eqmv- 
alent concentratmn of the sugar was added to con- 
trol tubes which did not contain IVIgG. lntraglobm 
F, 40 mg/ml, contained glucose 18 mg/ml m excess 
of glucose in HBSS Sandoglobuhn, 40 mg/ml, con- 
tamed sucrose 67 mg/ml. Gamlmune N, 40 mg/ml, 
contained maltose 80 mg/ml The control sugar 
concentrations are referred to below as "career-sug- 
ar'. 
pH e/lect o/II'IgG 
When added to HBSS Intraglobln F at 8 mg and 4 
mg/ml reduced the pH b}¢ 0.1 and 0 05 respectively. 
Sandoglobuhn reduced the pH by 0 02 and 0 01 In 
contrast, Gamlmune  N reduced the pH by 0 8 at 8 
mg/ml and by 0 3 at 4 mg/ml. Because of this effect, 
the highest final concentration of Gamlmune N 
used experimentally was 4 mg/ml A maximum 
drop in pH from 7 4 to 7 1 was considered accept- 
able in the assay systems of PMN funcuon 
Cell stimulants 
Particulate and soluble stimulants of  the neutrophll 
respiratory burst were employed to determine 
whether the stimulated response was too&fled by' 
the presence of IVIgG Opsonlzed zymosan (OZ) 
was used as the particulate stimulant. Zymosan 
(Sigma Chemical Co., St Louis, MO) was boiled m 
normal saline for 1 h, washed once m HBSS and 
resuspended in HBSS at 50 mg/ml as a stock sus- 
pension which was stored at 4°C Zymosan stock 
was opsonlzed by incubation with an equal volume 
of fresh normal human serum at 37°C for 30 tnln 
After washing twice in HBSS it was resuspended m 
HBSS at 10 mg/ml and stored at 4°C. OZ was used 
within one week of preparation Phorbol myrlstate 
acetate (PMA, LC Services Corp., Woburn,  MA) 
and N-formyl-L-methionyl-L-leucyl-L-phenylala- 
nine (FMLP,  Sigma Chemical Co., St. Louis, MO) 
were the soluble stimulants employed 
Chemoattractant 
Zymosan-activated serum (ZAS) was the standard 
chemoattractant.  Fresh human serum was incubat- 
ed with washed Zymosan (5 mg Zymosan to 1 ml of  
serum) at 37°C for 30 mm The Zymosan was spun 
down and the serum plpetted off. ZAS was aliquot- 
ted and stored at - 70°C. A 1/7 dilution of ZAS was 
used in all experiments 
Use o[ cell stimulants in resptratoo' burst assays 
OZ was added to the cells to a final concentration of  
1 mg OZ per 5 × 105 cells PMA was used at a final 
concentration of 10 ng/ml and F M L P  at 10 -6 M. In 
each case stock solution was diluted m HBSS to an 
appropriate  dilution and 0.1 ml of  this dilution was 
added to 0 9 ml of  the cell reaction mixture. The 
modifying effect of  IVlgG on the stimulation of the 
respiratory burst was also examined by adding 0.1 
ml of  the appropriate  dilution of IVIgG immediate- 
ly before the stimulant. 
Separation of neutrophtls Jrom blood 
Human  blood was taken from healthy volunteers 
and anticoagulated with preservative-free heparin 
(Elkms-Sinn Inc ,  Cherry Hill, NJ) at 10 U/ml of 
blood Neutrophlls were separated by buoyant  den- 
slty centnfugatlon over Flcoll /Hypaque according 
to the method of  Ferrante and Thong (1980). Seven 
ml of  blood were layered over 4 ml of  Neutrophil  
Isolation Medium (Los Alamos Dmgnostlcs, Los 
Alamos, NM) m a 15 ml tube and centrifuged at 400 
× g for 30 mm. After discarding the plasma and 
mononuclear  cell/platelet layers, the neutrophil lay- 
er was carefully separated using a Pasteur pipette 
and immediately diluted in HBSS. The neutrophfls 
together with the contaminating erythrocytes were 
spun down at 500 × g for 5 mln, and the erythro- 
cytes were lysed by 20 s exposure to distilled H20,  
99 
two cycles. Leukocytes were then washed once m 
HBSS, resuspended m HBSS and kept on ice until 
tested for respiratory burst actwity or chemotax~s. 
The final cell preparation contained 88 99% neu- 
trophfls (mean, 95 5%) and viability was greater 
than 99% by trypan blue exclusion. 
Superoxtde release assay 
Release of  superoxlde 1on ( 0 2 )  was measured by 
the superox~de dlsmutase (SOD) mhlbltable reduc- 
tion of  cytochrome c as described by McCord and 
Fridovlch (1969) The test was performed m 5 ml 
polypropylene tubes (Sarstedt, Numbrecht ,  W 
Germany).  Neutrophfls were suspended in HBSS to 
a concentration of 1 × 10 ° cells/ml: 0.5 ml of  cell 
suspension was added to each tube together with 1 
mg/ml of ferricytochrome c (Sigma Type III,  Sigma 
Chemical Co., St. Louis, MO). Control tubes con- 
tamed 0.023 mg/ml of SOD (Diagnostic Data, 
Mountamview, CA). Volumes were adjusted to 1 
ml with HBSS. Tubes were incubated in a shaking 
water bath for 20 mm at 37°C and the reaction was 
stopped in the tubes without SOD by adding 0.023 
mg of SOD m 100/A. The volumes m all tubes were 
then made up to 1.8 ml with HBSS and the cells 
were spun down at 1500 x g for 5 mm at 4°C 
Finally, the reduction of  cytochrome c was mea- 
sured by reading the absorbance of the supernatant 
at 550 nm in a spectrophotometer,  taking the SOD- 
containing supernatant as the reference. The differ- 
ence between the - SOD and + SOD tubes was cal- 
culated. Using an extinction coefficient of  18 5 
cm-1  mM 1 for cytochrome c (reduced-oxidized) 
at 550 rim, the difference in absorbance was mul- 
tiplied by 97 to obtain nm O2- /ml  (Margoliash and 
Frohwlrt, 1959). Addition of  IVIgG and stimulants 
was carried out as described above. 
Intracelhdar H202 production 
The assay used was that originally described by 
Keston and Brandt (1965) and adapted for flow cy- 
tometry by Bass et al. (1983). It depends on the use 
of  the nonfluorescent hydrophobic compound 2',7'- 
dlchlorofluorescln dlacetate (DCFH-DA)  which 
penetrates the cell membrane and is trapped lntra- 
cellularly by hydrolytic deacetylation to 2',7'-dl- 
100 
chlorofluorescln (DCFH) This compound is read- 
dy oxidized by H202, in the presence of peroxldase, 
to the fuorescent compound 2',7'-dmhlorofluores- 
celn (DCF). The conversion to DCF can be mea- 
sured by flow cytometry, thus giving a quantitative 
assessment of H,O2 productmn within the cells 
Freshly isolated neutrophds were suspended m PBS 
containing 0 1% gelatin, pH 7 4, at 5 5 × 10 s cells,' 
ml, DCFH- DA (Molecular Probes, Eugene, OR) 
was added to give a concentration of 20 t~M and the 
cells were Incubated at 37°C for 15 min To each 5 
ml polystyrene tube was added 0 45 ml of the 
DCFH-DA labelled cell suspension and after addi- 
tion of 0 05 ml of IVIgG and/or cell stimulant the 
tubes were incubated at 37°C for 45 mln m a water 
bath. Three thousand cells were examined in a flow 
cytometer (EPICS-541, EPICS DlvlSlOm Coulter 
Electronics, Hialeah, FL) equipped with an argon 
laser set at an excitation wavelength of 488 nm 
Green fluorescent emission (510-550 nm) was rec- 
orded Fluorescing neutrophlls were separated from 
other contaminating cell types by electronic gating 
Cell fluorescence was expressed as the mean channel 
number after correction for the gain setting of the 
photomultlpher tube Dose responses to IVlgG 
preparations were done w~th single samples In ex- 
periments to examine the modulating influence of 
IVlgG on the effect of cell stimulants, samples were 
run m triplicate 
C/WlT~IIhlIHlllCSCUII¢'¢ (IAS~IV 
The Lummol-amphfied chemdummescent response 
(CL) of neutrophlls was assayed essentially as de- 
scribed by Robinson and Penny (1982) Freshly, iso- 
lated neutrophlls were suspended in HBSS at 2 × 
105 cells.,"ml 0 5 ml ahquots of the cell suspension 
were added to glass scintillation vials, followed by 
0 05 ml of a 10 _3 M stock solution of 5-ammo-2,3- 
dlhydro-l,4-phthalazmedmne (Lumlnol, Eastman 
Kodak, Rochester, NY) and HBBS so that the final 
reaction volume was 1 ml IVIgG and/or stimulants 
were added and the vials were immediately placed 
in a hqmd sclntdlatlon counter (Beckman LS 5801, 
Beckman Instruments, Fullertom, CA) set for sin- 
gle-photon counting Chemiluminescence was mea- 
sured at ambient temperature (23°C). Samples were 
recycled for up to 1 h and CL was recorded as peak 
counts per minute (cpm). All CL experiments were 
performed using single samples because of the need 
to recycle vials at short time intervals to measure 
the peak CL response 
Chemotaxls assay 
This was performed by measuring the distance of 
cell migration through a 5 #m-pore-size nitrocellu- 
lose filter m a modified Boyden chamber Chemo- 
attractant (ZAS) or HBSS was plpetted into the 
lower chambers. The filters (Schlelcher & Schuell, 
Keene, NH) were saturated in HBSS containing 
0.1% BSA and clamped between the lower and up- 
per chambers Neutrophlls suspended in HBSS with 
0 1% BSA (1 5 × 1() ~ cells,,'ml) were dispensed into 
the upper chambers and cell migration was allowed 
to proceed at 37°C for 50 rain, after which the filters 
were stained w~th haematoxyhn The &stance of 
cell migration was measured by the leading-front 
method of Zlgmond and Hlrsch (1972) using a stan- 
dard mmroscope micrometer A reading was made 
in five different fields of each filter and the mean 
distance migrated was calculated m micrometers 
All assays were run in duplicate. The effect of 
IVIgG on chemoklnesls or ZAS-lnduced chemotax- 
is was examined by adding IVIgG or carrier-sugar 
to the cell suspension immediately, before dispens- 
ing cells into the chambers 
Staltslu'al analysts 
The significance of differences between test groups 
and controls was calculated using the one-tailed t 
test of Student 
Results 
Effect o/ IVIgG o n  0 2 - release and H20E ,~em, ratum 
The effect of the three IVIgG preparations on 02 
release by human neutrophlls m vitro was tested 
over a range of concentrations from 0 13 mg/ml to 8 
mg/ml The results are summarized in Table I SUm- 
ulatlon at levels of stahstlcal slgmficance was seen 
m the concentranon range 1-2 mg/ml. Sandoglobu- 
hn had the greatest s t lmulatory  effect, and  the max> 
m u m  increment  of  4.7 nm was seen at a dose of 1 
mg/ml.  In t r ag lobm F was lnhlbl tory  at the highest 
concen t r a tmn  used (8 mg/ml)  
To exclude the possibility that this sUmulatmn of 
O2-  release was simply due to protein,  h u m a n  se- 
rum a lbumin  (HSA) was added to neutrophi ls  at 
concent ra t ions  of 2 and 4 mg/ml  and O2-  release 
was compared with control  cells to which no HSA 
was added HSA mhlbl ted O 2 -  release at these con- 
centra t lons  
In contras t  to the effect on O2-  release, ln t raglo-  
bin F and Sandog lobuhn  resulted in increased 
H202 product ion  by neutrophfls  in a dose-depend- 
ent fashion up to the highest concent ra t ion  (8 mg/ 
ml) Peak s t imulat ion by G a m l m u n e  N was seen at 
l mg/ml (Fig. 1.) 
Fur ther  experiments were performed to deter- 
mine  whether IVIgG had any enhanc ing  or additive 
effect on st imulated 02  release and  H202 produc-  
non  when OZ, P M A  and  F M L P  were used a stim- 
ulants. The s t imulants  were added to the cells im- 
mediately after the IVIgG (or control  sugar 
solution).  The results of  these experiments are sum- 
m a n z e d  in Table  II Sandog lobuhn  enhanced 0 2 -  
release in the presence of all three st imulants ,  
whereas G a m l m u n e  N enhanced only F M L P  stlm- 
TABLE I 
Effect of IVIgG on O z release from human neutrophfls 
IVIgG AO 2 release (nmol) a 
(mg/ml) 
lntraglobln F Sandoglobulm Gamlmune N 
0 13 1 13 NT 0 44 
0 25 0 49 2 45 2 25 
05 l 46 3 14 230 
1 l 6 7  ~ 4 7 0  ~ 2 06 ~ 
2 2 55 ~ 3 58 ~ 3 43 
4 1 O3 3 53 ~ 2 79 
8 - 2  16 4 31 ~ NT ~ 
AO 2 release ,s the increase in 02- release in nanomoles per 5 
x l0 s cells above controls containing carrier-sugar m place of 
IVIgG 
h NT, not tested 
" p < 0 0 5  
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1 0 0 0  
: : I n t r a g l o b m  F 
8 0 0  ~- ~o S a n d o g l o b u h n  
G a r n l r n u n e  N 
6 0 0  
¢o 
4 0 0  
2 0 0  ~ -  ~ \ 
0 i I ~ l I i 
0 1 3  0 2 5  0 5 0  1 2 4 8 
)gG ( m g / m l )  
Fig l Effect of IVIgG on bI202 production The increase in 
lntracellular H202 is measured by the net increase in green fluo- 
rescence (."Ifluorescence) expressed as the increase m mean chan- 
nel number above controls The maximum channel number, af- 
ter correction for gain setting, was 2560 The assay' was mo&fied 
from Bass el al (1983) In this dose-response experiment, be- 
cause of strict time llm,tatlons m performing the assay on freshly 
prepared cells, single samples were assa)ed 
ulat lon and  In t rag lobm slgmficantly decreased 
P M A  st imulat ion.  
All three IVIgG preparat ions  enhanced the stlm- 
ulatory effects on H202 product ion,  with the single 
excepUon that  G a m l m u n e  N had no a d d m o n a l  ef- 
fect in the presence of PMA.  
Effect o f  lVIgG on neutrophd chemthml&escence 
Both In t rag lobm F and G a m i m u n e  N st imulated 
Luminol -amphf ied  chemiluminescence at concen- 
trat tons in the region of 0.5-1 mg/ml St lmulat ton 
indices (SI = peak st imulated cpm • peak control  
cpm) were in the range 1.5 to 2 3. Sandoglobuhn ,  on 
the other hand,  st imulated only at the highest dose 
(8 mg/ml),  SI 2 7. 
Assays were carried out  to determine the effect of  
the presence of IVIgG on CL st imulated by OZ par- 
tlcles. IVIgG (or control  sugar solution) was added 
to the cells immediately before the OZ. In t rag lobln  
had no additive effect and  was inhibi tory  at 4 and 8 
mg/ml Sandog lobuhn  and G a m i m u n e  N both 
showed a dose-dependent  enhanc ing  effect, maxi- 
mal at 1 mg/ml. The results using G a m i m u n e  N are 
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T A B L E  II 
Effect of  I V I g G  on  s t imula ted  O 2 release and H202  p r o d u c t m n  by h u m a n  neu t rophds  
IVIgG S m n u l a n l  h AO 2 {nmolp  p 
l n t r a g l o b m  F. 4 mg, 'ml O Z  - I 03 NS ~ 
P M A  8 58 0 048 
F M L P  1 27 NS ~ 
A F l u o r e s c e n c e '  p 
1277 110115 
660 11 006 
623 11 O05 
Sandoglobul ln .  4 mg, 'ml OZ 8 53 0 I}09 187 0 0{17 
P M A  9 51 0 01 227 01103 
F M L P  4 56 0 01 228 l) 002 
G a m l m u n e  N.  1 mg,,ml O Z  I 96 NS ~ 347 0 0002 
P M A  2 99 NS ~ 111 NS ~ 
F M L P  7 74 (1 002 197 0 0003 
" AO 2 ~s the increase m O 2 release m nanomole s  per  5 x 111 ~ cells. 1Fluorescence  ~ the net increase m green fluorescence expressed as 
the increase m mean  channe l  n u m b e r  abo~e cont ro ls  c o n t a l m n g  app rop rmte  ca r ee r - suga r  m place of  I V l g G  
b OZ,  1 mg,'ml, P M A ,  l0  ng/ml ,  F M L P ,  10 6 M 
NS - no t  s~gmficant, p > 0 05 
shown m Table III, and the effect of Sandoglobuhn 
ts shown m Fig. 2 
Effect of lVIgG on neutrophtl locomotion and chemo- 
t a x i s  
In th~s part of the study only three concentrations 
of IVIgG were utthzed' 0.25, 1 and 4 mg/ml When 
the lower chamber contamed only HBSS, migration 
T A B L E  III  
Enhanc ing  effect o f  G a m l m u n e  N on neutrophf l  chemdumlnes -  
cence response  to O Z  0 2 mg /ml  
G a m l m u n e  N ACL" S h m u l a t l o n  
lmg, 'ml) l cpm x 10 -~') index ~ 
0 2 5  2 0 4  1 71 
0 5 36 7 2 52 
1 36  5 281 
2 2 7 2  2 16 
4 4 95 l 22 
8 - 14 4 ~ 0 47 
' ACL ,  increase m peak chemi luminescence  response  above  
cont ro ls  c o n t a l m n g  ea rne r -ma l to se  in place of  1VIgG 
b S t imula t ion  index, raUo of  peak  C L  responses  wi th  and with-  
out  I V I g G  
Depressed  response  p r o b a b l y  accounted  for by fall in pH at 
highest  concen t r a tmns  of  Gam~mune  N 
of cells through the filter was significantly increased 
only by Intraglobm 0.25 mg/ml and Gamlmune N l 
mg/ml ZAS-mduced directed migration of neutro- 
T A B L E  IV 
Effect o f  1VlgG on neut rophl l  l o c o m o t m n  and ZAS-mduced  di- 
rected mig ra t ion  
1VIgG 
(mg,,ml) 
ACell migra t ion  (l~m) ~ 
HBSS ZAS m 
lower  chambe r  lower c h a m b e r  
I n t r ag lobuhn  0 25 12 4 b 0 1 
I 1 2 2  - 9 4  
4 3 8  - 1 9 9  
Sandog lobuhn  0 2 5  - 13 - 1 2 2  
1 - 1 0 3  - 1341 
4 6 3  - 1~ 
G a m l m u n e  0 2 5  7 5  179 
1 24 8 b 46 4 
4 275  132 ~ 
dCe l l  migra t ion ,  increase m dis tance  t ravel led compared  to 
con t ro l  cells with ca r ee r - suga r  m place of  1VIgG (A ncga twe  
value ln&cates  an actual  decrease in d~stance t ravel led com- 
pared  to cont ro l  cells ) 
b p < 0 05 
Cells migra ted  th rough  filters Figure  is increase m mean  cells 







c-~--o Sandoglobuhn lmg/ml 
+ OZ 2mg/ml 
Sucrose 1 7rng/rnl 
+ OZ 2mg/ml S " ' ,n. 
¢" - ,  
t~ 
/ v s 
/ 
/ 
,0 20 30 40 5; 6'0 ,'0 
TIME (MINS) 
Fig 2 Enhancing effect of Sandoglobuhn 0 2 mg/ml on neutro- 
phil chemdummescence response to opsonlzed zymosan Con- 
trols contained sucrose 1 7 mg/ml in place of IVIgG In order to 
recycle wals as rapidly as possible tn the counter, single samples 
were assayed 
phIls was decreased by most concentrations of  In- 
traglobin and Sandoglobuhn, and in the presence of 
Gamlmune N migration was increased, these differ- 
ences &d not reach levels of  statistxcal s~gnificance 
(Table IV). 
Discuss ion  
Various mechanisms have been proposed to explain 
how IVIgG reduces cell destruction in the immune 
cytopenias (Imbach, 1983). The most popular theo- 
ry is that IVIgG interacts with Fc receptors of  
mononuclear phagocytes, thereby inhibiting the 
phagocytosis of  cells (red cells, platelets or neutro- 
phils) opsonlzed by autoantibody (or alloantibody). 
There ts in vitro experimental evidence to support 
this concept (Jungi et al., 1986). An equally attrac- 
tive hypothesis is that infused immunoglobuhn 
binds to red blood cells which are then preferential- 
ly sequestered by macrophages; support for this 
mechanism is provided by the chnlcal findlng that 
the injection of anti-Rho(D) ts effective an treating 
ITP (Salama et al., 1983, Baghn et al., 1986). In 
addiUon to the effect of macrophage blockade, 
IVIgG may modulate the immune response by al- 
tering the proportions of  T-cell subsets or by n o n -  
specific inhibition of  B-cell responsiveness (Tsubla- 
klo et al., 1983; Dammacco et al., 1986; Stohl, 
1986). 
The beneficial effect of IgG replacement therapy 
in hypogammaglobulinemla is presumably due 
largely to passive immunization with preformed 
specific antibodies; such antibodies against a w~de 
range of bacterial and vtral pathogens can readily 
be demonstrated in human IgG for both IV and IM 
use (Yap, 1987). However, experimental and clin- 
ical evidence indicates that IVIgG may interact with 
macrophage Fc receptors and, in other unspecified 
ways, modulate the immune response, as already 
discussed This raises the possibility that ~t may also 
mfluence neutrophll function. Koch et al. (1984) 
showed that IVIgG can stimulate neutrophil 0 2 -  
release and chemiluminescence in wtro; the present 
study was designed to further mvestigate this effect. 
The neutrophll respiratory burst was examined us- 
mg three assays; O 2 - release, H202 production and 
Lummol-dependent chemiluminescence (CL). The 
CL response of activated neutrophlls correlates well 
with metabohc activation (Allen et a l ,  1972), but 
there has been considerable controversy as to what 
is the chief oxidizing species measured in Lumlnol- 
dependent CL. De Chatelet and Shirley (1981) have 
argued that it is largely due to HOCI which diffuses 
extracellularly and reacts with Luminol to form 
amlnophthalate ions and hght generation. 
In all three types of  assay our results indicated 
that IVIgG can directly stimulate the neutrophll re- 
spiratory burst. The maximum increase in O2- re- 
lease was of the order of  3.5-4.55 nmol (per 5 × 105 
cells) and this was achieved by concentrations of 
0.5-1 mg/ml IVIgG, concentrations which are read- 
fly achieved in moderate-dose IVIgG therapy. 
High-dose therapy can achieve serum concentra- 
tions of  the order of  8 mg/ml (Pirofsky, 1987). In 
the case of  H202 production, the stlmulatory effect 
on H202 was more clearly dose-dependent, and for 
two IVIgG preparations it appeared that the maxi- 
mal H202 response was not reached in the range of 
concentrations used. The sttmulatory effects of OZ, 
PMA and F MLP  were enhanced by IVIgG and this 
enhancing effect was more clearly seen in the H202 
assay. 
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CL responses also indicated that IVIgG can di- 
rectly stimulate neutrophils, as well as being able to 
enhance the metabolic response following ingestion 
of OZ. 
There are few published reports on the effects of 
IVlgG on neutrophlls, either m VlVO or in vitro. 
Koch et al (1984), using a blood leukocyte prep- 
aration conslstmg of both neutrophils and mononu- 
clear cells, demonstrated that the neutrophfl respi- 
ratory burst was stimulated in vitro by IVlgG, The 
mammal increases in 0 2 -  release, 5 nmol per 10 ~' 
cells, was quite consistent with our own findmgs. 
Redde t  al (1988) reported that human IVIgG re- 
duced the severity of neutropenla in newborn rats 
after lntrapulmomc mJecnon of group B streptococ- 
ci This was thought to be due to increased release 
of neutrophlls from the marrow and egress from the 
blood mto infected tissue IVIgG did not affect the 
production of neutrophfls in vitro or in VlVO 
Of the three IVIgG preparatmns used m the pres- 
ent study, Intraglobln F (Blotest) has the highest 
content of dlmers and aggregates (Lundblad et a l ,  
1987). If the observed stimulation of neutrophfls 
was initiated by the mteraction of aggregated IgG 
with Fc receptors, we would have expected Intra- 
globln F to give consistently higher levels of stim- 
ulation This was not observed Monomerlc IgG is 
known to attach to Fc receptors of human mono- 
cytes (Kurlander, 1980) and, in the same way, must 
be able to bmd to Fc receptors of neutrophils. The 
stimulating effect of IVIgG on neutrophfl metabo- 
hsm could not be reproduced by another serum pro- 
tem (HSA), suggesting that Fc receptor monomerlc 
IgG interaction may be the lnltlatmg event 
There is no doubt that the benefit of IVIgG ther- 
apy in hypogammaglobuhnemla, and m severe in- 
fection in the tmmunocompromtsed host, is primar- 
ily due to the passive provision of preformed 
antibodies. However, the findings of this study sug- 
gest that host defence may benefit secondarily from 
the direct stimulation of neutrophll metabohsm by 
IVIgG 
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